Yüklüyor......
Long-Term Clinical Benefits of a Platelet Glycoprotein IIb/IIIa Receptor Blocker, Abciximab (ReoPro(®)), in High-Risk Diabetic Patients undergoing Percutaneous Coronary Intervention
BACKGROUND: High-risk percutaneous coronary interventions (PCIs) are associated with a high complication rate, a low procedural success rate and a high restenosis rate, especially in diabetics. We sought to determine whether abciximab (ReoPro(®)) therapy affects long-term clinical outcomes of Korean...
Kaydedildi:
| Yayımlandı: | Korean J Intern Med |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Korean Association of Internal Medicine
2003
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4531627/ https://ncbi.nlm.nih.gov/pubmed/14619381 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3904/kjim.2003.18.3.129 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|